Multi-pathway targeting by natural products in chronic respiratory diseases: Opportunities, challenges, and future perspectives

IF 11.2 4区 医学 Q1 CHEMISTRY, MEDICINAL
Chinese Herbal Medicines Pub Date : 2026-07-01 Epub Date: 2026-05-08 DOI:10.1016/j.chmed.2026.05.003
Siqi Lin, Lili Li, Shiqing Zhuo, Liang Yu, Yu Huang, Xiaofei Chen, Huihui Ti
{"title":"Multi-pathway targeting by natural products in chronic respiratory diseases: Opportunities, challenges, and future perspectives","authors":"Siqi Lin,&nbsp;Lili Li,&nbsp;Shiqing Zhuo,&nbsp;Liang Yu,&nbsp;Yu Huang,&nbsp;Xiaofei Chen,&nbsp;Huihui Ti","doi":"10.1016/j.chmed.2026.05.003","DOIUrl":null,"url":null,"abstract":"<div><div>Chronic respiratory diseases (CRDs) are multifactorial disorders driven by dysregulated inflammation, oxidative stress, and tissue remodeling. Conventional single-target therapies are insufficient to halt disease progression, underscoring the demand for alternative therapeutic approaches. Natural products, including bioactive compounds, herbal extracts, and traditional Chinese medicine (TCM) formulas, are characterized by their inherent multi-target properties and represent a promising intervention strategy for CRDs. This perspective emphasizes natural products as network modulators that can simultaneously regulate multiple signaling pathways. The integration of systems biology, network pharmacology, and artificial intelligence (AI) is crucial for deciphering their polypharmacological mechanisms. The clinical translation of natural products is anticipated to benefit from the implementation of several key strategies, including multi-omics integration, AI, targeted delivery, and blockchain-based quality control. By shifting from a reductionist to a network-centric view, natural products can fulfill their potential as next-generation therapeutics for CRDs.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 3","pages":"Pages 638-642"},"PeriodicalIF":11.2000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389992/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Herbal Medicines","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1674638426000559","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic respiratory diseases (CRDs) are multifactorial disorders driven by dysregulated inflammation, oxidative stress, and tissue remodeling. Conventional single-target therapies are insufficient to halt disease progression, underscoring the demand for alternative therapeutic approaches. Natural products, including bioactive compounds, herbal extracts, and traditional Chinese medicine (TCM) formulas, are characterized by their inherent multi-target properties and represent a promising intervention strategy for CRDs. This perspective emphasizes natural products as network modulators that can simultaneously regulate multiple signaling pathways. The integration of systems biology, network pharmacology, and artificial intelligence (AI) is crucial for deciphering their polypharmacological mechanisms. The clinical translation of natural products is anticipated to benefit from the implementation of several key strategies, including multi-omics integration, AI, targeted delivery, and blockchain-based quality control. By shifting from a reductionist to a network-centric view, natural products can fulfill their potential as next-generation therapeutics for CRDs.
天然产物在慢性呼吸系统疾病中的多途径靶向:机遇、挑战和未来展望
慢性呼吸系统疾病(CRDs)是由炎症失调、氧化应激和组织重塑驱动的多因素疾病。传统的单靶点治疗不足以阻止疾病进展,这强调了对替代治疗方法的需求。天然产物,包括生物活性化合物、草药提取物和中药配方,以其固有的多靶点特性为特征,代表了一种很有前途的crd干预策略。这种观点强调天然产物作为网络调节剂,可以同时调节多种信号通路。系统生物学、网络药理学和人工智能(AI)的整合对于破译它们的多药理机制至关重要。天然产品的临床翻译预计将受益于几个关键策略的实施,包括多组学集成、人工智能、有针对性的交付和基于区块链的质量控制。通过从简化论者转向以网络为中心的观点,天然产物可以发挥其作为crd下一代治疗药物的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chinese Herbal Medicines
Chinese Herbal Medicines CHEMISTRY, MEDICINAL-
CiteScore
4.40
自引率
5.30%
发文量
629
审稿时长
10 weeks
期刊介绍: Chinese Herbal Medicines is intended to disseminate the latest developments and research progress in traditional and herbal medical sciences to researchers, practitioners, academics and administrators worldwide in the field of traditional and herbal medicines. The journal's international coverage ensures that research and progress from all regions of the world are widely included. CHM is a core journal of Chinese science and technology. The journal entered into the ESCI database in 2017, and then was included in PMC, Scopus and other important international search systems. In 2019, CHM was successfully selected for the “China Science and Technology Journal Excellence Action Plan” project, which has markedly improved its international influence and industry popularity. CHM obtained the first impact factor of 3.8 in Journal Citation Reports (JCR) in 2023.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书